|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:clinicalTrials.govID
|
gptkb:NCT01327846
|
|
gptkbp:conditionStudied
|
myocardial infarction
atherosclerosis
|
|
gptkbp:country
|
multiple countries
|
|
gptkbp:eligibility
|
history of myocardial infarction and elevated hsCRP
|
|
gptkbp:endDate
|
2017
|
|
gptkbp:fullName
|
gptkb:Canakinumab_Anti-inflammatory_Thrombosis_Outcomes_Study
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CANTOS trial
|
|
gptkbp:intervention
|
gptkb:monoclonal_antibody
|
|
gptkbp:mechanismStudied
|
IL-1β inhibition
|
|
gptkbp:participants
|
10,061
|
|
gptkbp:period
|
Phase III
|
|
gptkbp:principalInvestigator
|
gptkb:Paul_M._Ridker
|
|
gptkbp:publishedIn
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:result
|
canakinumab reduced recurrent cardiovascular events
canakinumab increased risk of fatal infection
reduction in recurrent cardiovascular events
|
|
gptkbp:resultPublicationYear
|
2017
|
|
gptkbp:significance
|
provided evidence for inflammation hypothesis of atherosclerosis
|
|
gptkbp:sponsor
|
gptkb:Novartis
|
|
gptkbp:startYear
|
2011
|
|
gptkbp:studiedDrug
|
gptkb:canakinumab
|
|
gptkbp:bfsParent
|
gptkb:Paul_Ridker
|
|
gptkbp:bfsLayer
|
5
|